SCHEMBL4451845

SCHEMBL4451845

CCCCCCCCC=CCCCCCCCC(=O)OC(CN(C)C)C(CN(C)C)OC(=O)CCCCCCCC=CCCCCCCCC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 2/20 0.56
PRKCE Q02156 1/20 0.56
PRKCQ Q04759 1/20 0.56
PRKCD Q05655 1/20 0.56
FAAH O00519 3/20 0.52
MAPT P10636 3/20 0.52
ALDH1A1 P00352 1/20 0.52
HPGD P15428 1/20 0.52
CNR1 P21554 1/20 0.52
CNR2 P34972 1/20 0.52
DGKA P23743 1/20 0.51
SLC6A5 Q9Y345 1/20 0.51
TERT O14746 3/20 0.50
LMNA P02545 2/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2C19 P33261 2/20 0.50
BLM P54132 2/20 0.50
HSD17B10 Q99714 2/20 0.50
FABP4 P15090 2/20 0.50
PTPN1 P18031 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4458170 1.00 PRKCA (0.56) PRKCAPRKCEPRKCQPRKCDFAAH
SCHEMBL23923637 0.93 PRKCA (0.50) PRKCAPRKCEPRKCQPRKCDFAAH
SCHEMBL21014331 0.91 FAAH (0.61) PRKCAPRKCEPRKCQPRKCDFAAH
SCHEMBL26613661 0.91 LMNA (0.59) PRKCAPRKCEPRKCQPRKCDMAPT
SCHEMBL15668671 0.91 PRKCA (0.47) PRKCAPRKCEPRKCQPRKCDFAAH
SCHEMBL29168493 0.90 PRKCA (0.50) PRKCAPRKCEPRKCQPRKCDFAAH
SCHEMBL28372017 0.88 PRKCA (0.52) PRKCAPRKCEPRKCQPRKCDFAAH
SCHEMBL20985468 0.87 ALDH1A1 (0.53) PRKCAPRKCEPRKCQPRKCDFAAH
SCHEMBL465985 0.87 PRKCA (0.54) PRKCAPRKCEPRKCQPRKCDFAAH
SCHEMBL992184 0.87 PRKCA (0.54) PRKCAPRKCEPRKCQPRKCDFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598421-B2 Materials for the delivery of biologically-active material to cells UCL BIOMEDICA PLC (GB) 2009-10-06 US disclosed
US-20050245446-A1 Materials for the delivery of biologically-active material to cells NANOGENICS LIMITED (GB) 2005-11-03 US disclosed
EP-1506019-A1 COMPLEXES FOR THE DELIVERY OF BIOLOGICALLY-ACTIVE MATERIAL TO CELLS University College London (GB) 2005-02-16 EP disclosed
WO-2003094974-A1 COMPLEXES FOR THE DELIVERY OF BIOLOGICALLY-ACTIVE MATERIAL TO CELLS UNIVERSITY COLLEGE LONDON (GB) 2003-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245446-A1 Materials for the delivery of biologically-active material to cells ITGB1, ITGA2B, ITGB2 PRKCA 4450/4885PRKCE 4616/4885PRKCQ 4095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.